Elanco Animal Health Inc. is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018. Since then, Elanco has pursued strategic acquisitions to strengthen its global footprint and expand its R&D capabilities. A notable milestone was the 2020 acquisition of Bayer’s Animal Health business, which added complementary products and bolstered Elanco’s presence across Europe, Latin America, Asia-Pacific and North America.
Elanco operates a network of research centers, manufacturing sites and distribution facilities around the world, enabling it to serve customers in more than 90 countries. The company invests in collaborations with universities, industry partners and veterinarians to advance its pipeline of biologics and pharmaceuticals. Under the leadership of President and Chief Executive Officer Jeffrey Simmons, Elanco continues to focus on innovation, sustainability and responsible use of medicines to address emerging health challenges in animal agriculture and companion care.
AI Generated. May Contain Errors.
